Public Defence: Birgitte Stiksrud
Cand.med. Birgitte Stiksrud at Instiute of Clinical Medicine will be defending the thesis “Chronic immune activation and inflammation in HIV-infected immunological non-responders: A study of innate and adaptive immunity and effect of probiotic intervention” for the degree of PhD (Philosophiae Doctor).
Trial Lecture – time and place
See Trial Lecture.
- First opponent: Assistant Professor Gitte Kronborg, University of Copenhagen, Denmark
- Second opponent: Assistant Professor Marcus Buggert, Department of Medicine Huddinge, Karolinska Institutet, Sweden
- Third member and chair of the evaluation committee: Associate Professor Jan Erik Berdal, University of Oslo
Chair of the Defence
Professor Torgeir Bruun Wyller, Faculty of Medicine, University of Oslo
Professor II Anne Margarita Dyrhol Riise, Faculty of Medicine, University of Oslo
Despite modern antiretroviral therapy (ART) and persistent viral suppression, approximately 12-30% of people living with HIV (PLWH) do not normalize their CD4+ T cell count, denoted immunological non-responders (INR). INR have increased risk of developing AIDS defining illnesses, non-AIDS related morbidities and higher mortality, probably in part caused by increased chronic immune activation and inflammation. Alterations in the gut microbiota and destruction of the gut mucosal barrier with subsequent leakage of microbial products into the systemic circulation could be one of the sources of chronic inflammation.
This thesis aimed to characterize differences in chronic immune activation and inflammation between a cohort of INR and a cohort of ART-treated PLWH with adequate CD4 recovery, to search for biomarkers for incomplete CD4 gain on ART and to evaluate the effects of probiotic intervention in virally suppressed PLWH with a subnormal CD4 count. The patients were recruited from Oslo University Hospital with contribution from Karolinska University Hospital. Blood and fecal samples were collected.
The INR cohort displayed a more activated innate and adaptive immune system compared with PLWH on ART with normalized CD4 counts. In particular, plasma interferon-inducible protein 10 (IP-10) was increased in the INR cohort and associated with reduced future CD4 recovery. In a randomized controlled pilot study, eight weeks of intervention with a multistrain probiotic was well tolerated, induced shifts in the gut microbiota consistent with the probiotic strains administered, and seemed to reduce markers of coagulation and inflammation.
These findings contribute to the understanding of the immunological mechanisms causing an inadequate CD4 recovery in INR. The usefulness IP-10 as a potential biomarker for incomplete CD4 gain in clinical practice, as well as the potential beneficial effect of probiotic intervention have to be further elaborated in larger prospective studies.
Contact the research support staff.